Oral Linezolid Induced Early Onset Hepatic Encephalopathy- A Case Report of 65-year Old Diabetic Female
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Linezolid is increasingly utilized to treat gram-positive bacteria that are resistant to other antibiotics like vancomycin-resistant Staphylococcus aureus, methicillinresistant Staphylococcus aureus as well as drug-resistant tuberculosis. It acts by inhibiting protein synthesis in bacteria. Although it is a relatively safe medicine, many reports of hepatotoxicity and neurotoxicity linked to long-term usage have been received but patients with pre-existing risk factors, such as diabetes and alcoholism, may have toxicity even after short-term use of linezolid.
CASE PRESENTATION: Here we are presenting a case of a 65-year-old female with diabetes who developed hepatic encephalopathy after one week of treatment with linezolid prescribed for nonhealing diabetic ulcer after a culture sensitivity test. After the use of linezolid 600 mg BD for 8 days patient developed altered sensorium and breathlessness and had high bilirubin, SGOT, and SGPT. She was diagnosed with hepatic encephalopathy. Linezolid was withdrawn and after 10 days all laboratory parameters for liver function test were improved.
CONCLUSION: Care should be taken when prescribing linezolid in such patients with pre-existing risk factors as they are prone to develop hepatotoxic and neurotoxic adverse effects even after short-term use of linezolid.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current drug safety - 19(2023), 1 vom: 30., Seite 151-153 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Upadhyay, Mitul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetamides |
|---|
| Anmerkungen: |
Date Completed 28.11.2023 Date Revised 28.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574886318666230417113910 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355743582 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355743582 | ||
| 003 | DE-627 | ||
| 005 | 20231226065005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886318666230417113910 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355743582 | ||
| 035 | |a (NLM)37070438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Upadhyay, Mitul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Linezolid Induced Early Onset Hepatic Encephalopathy- A Case Report of 65-year Old Diabetic Female |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2023 | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Linezolid is increasingly utilized to treat gram-positive bacteria that are resistant to other antibiotics like vancomycin-resistant Staphylococcus aureus, methicillinresistant Staphylococcus aureus as well as drug-resistant tuberculosis. It acts by inhibiting protein synthesis in bacteria. Although it is a relatively safe medicine, many reports of hepatotoxicity and neurotoxicity linked to long-term usage have been received but patients with pre-existing risk factors, such as diabetes and alcoholism, may have toxicity even after short-term use of linezolid | ||
| 520 | |a CASE PRESENTATION: Here we are presenting a case of a 65-year-old female with diabetes who developed hepatic encephalopathy after one week of treatment with linezolid prescribed for nonhealing diabetic ulcer after a culture sensitivity test. After the use of linezolid 600 mg BD for 8 days patient developed altered sensorium and breathlessness and had high bilirubin, SGOT, and SGPT. She was diagnosed with hepatic encephalopathy. Linezolid was withdrawn and after 10 days all laboratory parameters for liver function test were improved | ||
| 520 | |a CONCLUSION: Care should be taken when prescribing linezolid in such patients with pre-existing risk factors as they are prone to develop hepatotoxic and neurotoxic adverse effects even after short-term use of linezolid | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Linezolid | |
| 650 | 4 | |a OD | |
| 650 | 4 | |a diabetic. | |
| 650 | 4 | |a hepatic encephalopathy | |
| 650 | 4 | |a hepatotoxicity | |
| 650 | 4 | |a oxazolidinone | |
| 650 | 7 | |a Linezolid |2 NLM | |
| 650 | 7 | |a ISQ9I6J12J |2 NLM | |
| 650 | 7 | |a Oxazolidinones |2 NLM | |
| 650 | 7 | |a Acetamides |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Purohit, Bhargav |e verfasserin |4 aut | |
| 700 | 1 | |a Pargi, Piyush |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 19(2023), 1 vom: 30., Seite 151-153 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:1 |g day:30 |g pages:151-153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886318666230417113910 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 1 |b 30 |h 151-153 | ||